Biochemical study of survivin -31G/C promoter polymorphism in breast Cancer

Document Type : Original Article

Authors

1 Debartment of Biochemistry, Faculty of Medicine, Sohag University.

2 Department of Medical Biochemistry, Faculty of Medicine, Assiut University.

3 Department of Medical Biochemistry, Faculty of Medicine, Tanta University.

4 Department of Biochemistry, Faculty of Medicine, Sohag University.

5 Departmentof Biochemistry, Faculty of Medicine, Sohag University.

Abstract

   Breast cancer is the most common cancer and also the leading cause of cancer mortality in women worldwide.
   Survivin is a member of the inhibitor of apoptosis (IAP) family, which has been identified recently. Unlike other IAP proteins, survivin is generally not found in normal adult tissues but notably expressed in the most common human cancers including stomach, colorectal, lung and breast.
   In cancer cells, overexpression of survivin at both protein and mRNA levels is linked to genetic variant -31G/C in the survivin promoter.  
   P53-Abs were discovered 20 years ago during the course of tumor-associated antigens screening. The discovery of p53 mutation and accumulation of p53 in human tumors shed new light on the p53 humoral response.
The aim of work: investigate -31 G/C single nucleotide polymorphism (SNP)of survivin promoter in breast cancer patients.Measurement of the level of p53 antibodies in them and detecting the association between it and the polymorphism also.
Patients and methods: 100 subjects were enrolled in this study. All were women in the age between 40 and 65 (60 breast cancer cases and 40 control divided into two groups according to age: Group 1 ≤ 50 years (27.3 ± 4.87) and Group 2 > 50(24.83 ± 6.12).
Results: Our study shows a significant difference in the prevalence of the survivin promoter polymorphism (–31G > C) between the case and control groups, P-value (P = 0.005*).  Notably, the combined prevalence of the GC and CC genotypes (GC + CC), reflecting the prevalence of the C allele, was significantly greater in the breast cancer group than in the control group (P= 0.002*) with rates of 29% and 6%, respectively. These results imply that the C allele at position –31 in the promoter region of the survivin gene increases an individual’s susceptibility to breast cancer.
     Also, the risk of developing cancer was 4.05 times higher in patients with the GC or CC genotype (GC + CC) than in patients with the GG genotype, and this difference was statistically significant (95% CI: (1.48 – 11.09).
     Besides, in the breast cancer group, the GG genotype was present in 35 patients, whereas the GC + CC genotype was present in 25 patients.
      As regards the level of p53 antibodies, there was a significant difference (p=0.025) between cases (11.67±11.96) and controls (4.65 ± 0.48). But, no significant difference in the different genotypes of breast cancer patients(p=0.83).
Conclusion Survivin promoter -31 G/C polymorphism is associated with the risk of developing breast cancer. C allele at position –31G/C in the promoter region of the survivin gene increases an individual’s susceptibility to breast cancer. As regards the level of p53 antibodies, there was a significant difference between cases and controls. But, no significant difference in the different genotypes of breast cancer patients.The presence of p53 Abs could be a useful marker to complement routine prognostic factors in breast cancer patients.

Main Subjects

References

  1. Siegel RL, Miller KD and Jemal A(2015): Cancer statistics,. CA Cancer J Clin 65: 5-29.
  2. Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, Mirmiran A, Khorsandi MT, Larijani B, Mostaan LV et al. (2012): Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 15; 208: 100–103.
  3. Ambrosini G, Adida C and Altieri DC.(1997): A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Mad ; 3: 917-21.
  4.  Perez LO, Abba MC, Dulout FN, Golijow CD.(2006): Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol; 12: 1426-9.
  5.  Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. (2008): Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer; 8: 32.
  6.  Jaiswal PK, Goel A, Mandhani A, Mittal RD(2012): functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 2012; 39 : 5615-21.
  7. Ding L, Zhang Z, Xu Y and Zhang Y(2017): Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered 8: 383-392, 2017.
  8. Parsa Y, Mirmalek SA, Kani FE, Aidun A, Salimi-Tabatabaee SA, Yadollah-Damavandi S, Jangholi E, Parsa T and Shahverdi E(2016): A review of the clinical implications of breast cancer biology. Electron Physician 8: 2416-2424.
  9. Khan Z, Khan AA, Yadav H, Prasad GBKS and Bisen PS(2017): Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell Mol Biol Lett 22: 8.
  10. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, Fujii M, Hatano M, Tokuhisa T and Mori N(2005): Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 115: 967-974.
  11.  Wilson JM, Kunnimalaiyaan S, Kunnimalaiyaan M and Gamblin TC(2015): Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell Int 15: 13.
  12. Mirza A, McGuirk M, HocekberryTN, et al.,(2002): Human survivin is negatively regulated by wild-type p53 and participates in the p53-dependent apoptotic pathway. Oncogene 2002;21:2613 ^ 22.
  13. HoffmanWH, Biade S, Zilfou JT, Chen J, Murphy M.(2002): Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277: 3247 ^ 57. 32. Mora LB, Buettner R, Seigne J, et al. Constitutive
  14. Zaffaroni N, Pennati M, Colella G, et al. (2002): Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002;59:1406 ^ 12.
  15. Song Z, Yao X, Wu M.(2003): Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol induced apoptosis. JBiol Chem 2003;278:23130.
  16. Islam A, Kageyama H, Takada N, et al.(2000): High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene ;19:617 ^ 23.
  17.  Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M.(2010): Effects of caspase-9 and surviving gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 2010; 39 : 976-80.
  18. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK and Lee HY(2007): Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 67: 11630-11639, 2007.
  19. Rasool, I., Wani, K. A., Yousuf, A., Bhat, I. A., Rah, B., Nazir, S. U., .and  Dubey, S, (2017): Role of the Functional Polymorphism of Survivin Gene (-31G/C) and Risk of Breast Cancer in a North Indian Population. Clinical breast cancer. 22: 35–37.
  20. Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, Mirmiran A, Khorsandi MT, Larijani B, Mostaan LV et al. (2012): Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 15; 208: 100–103.
  21. Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, Mahrampour E, Larijani B, Tavakkoly-Bazzaz J, and Amoli MM,(2012):Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer 22: 35–37.
  22. Rojhannejad M, Hoseinpourfeizi MA, Pouladi N, Arab MR and Mohamadi M(2015): The association between survivin   -31G/C promoter polymorphism and breast cancer in Eastern Azerbaijan, Iran. Zahedan J Res Med Sci. 2015; X(X): XX-XX ).
  23. Yamamoto S1, Chishima T1, Adachi S1, Harada F1, Toda Y1, Arioka H1, Hasegawa N1 and  Kakuta Y,(2014 ): Serum p53 antibody in breast cancer.;14(4):203-6.
  24. Ahmed M. Domaa and Maha S. Ali and 3Hesham A. M. and Gomaa,(2012): Comparison Between Serum Soluble Fas, P53 and Serum Ca 15-3 in Breast Cancer Patients.Australian Journal of Basic and Applied Sciences, 6(7): 475-482.
  25. Müller M1, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, Stremmel W, Volkmann M, Galle PR(2006):Int J Oncol. Oct;29(4):973-80.
  26. Keyhani, M., S. Nasizadeh, A. and Dehghannejad, (2005): Serum CA 15-3 measurement in breast cancer patients before and after mastectomy. Arch Iranian Med., 8: 263-6.311.
  27. Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A., and Bunting, P. S. (1994):  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58: 

Files

Share

How to cite

Statistics